Federal Trade Commission/Eye Research Associates.
This article was originally published in The Gray Sheet
Consent agreement proposed by FTC in a Feb. 25 Federal Register notice would settle claims that ERA made "false, unsubstantiated" and "deceptive" claims in direct-to-consumer print advertisements and videotapes in promoting its "Controlled Kerato Reformation orthokeratology (CKR Ortho-K) service. Ortho-K is a non-surgical process in which a patient wears, usually while asleep, custom-designed extended-wear contact lenses that reshape the corneal curvature of the eye. FTC proposes that the company remove from advertisements certain claims, including one stating that the procedure corrects myopia and astigmatism, "thereby permanently eliminating the need for eyewear." FTC is seeking public comment on the proposed consent order by April 27. FDA's Ophthalmology Devices Panel raised concern with Ortho-K at a Feb. 12 meeting; the agency is developing guidance for manufacturers of Ortho-K lenses following a recent FDA decision to require approval of a premarket approval application ("The Gray Sheet" Feb. 23, p. 9)...
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.